As shown in Table 1, T3/T4 stage, lymph node metastasis, distant metastasis, and stage III/IV patients accounted for 14.8%, 35.2%, 6.3%, and 24.8%, respectively, in the RPL22L1 high-expression group, whereas it accounted for 10.4%, 29%, 3%, and 16%, respectively, in the low-expression group. Here, RPL22L1 is linked to metastatic malignant neoplasm in the lymph nodes.